Treatment with the immune-modulating peptide thymosin alpha-1 reduced mortality from 50% to 25% in rats with severe acute pancreatitis by boosting T-cell immunity and reducing inflammatory markers.
Mortality halved: 50% → 25%Thymosin alpha-1 treatment reduced death rate in severe acute pancreatitis rats while boosting CD3+, CD4+, and CD8+ T-cell counts
What the researchers found
In 144 rats randomized to four groups, treatment with thymosin alpha-1 (26.7 µg/kg IV) after SAP induction produced significant improvements:
Survival: Mortality reduced from 50% (6/12) in untreated SAP to 25% (3/12) with TA1 treatment
Immune function: Significantly increased CD3+, CD4+, and CD8+ T-cells and improved CD4+/CD8+ ratio compared to untreated SAP
Inflammatory markers: Significantly lower levels of AST, LDH, α-amylase, P-type amylase, lipase, procalcitonin, TNF-α, IL-4, IL-5, and IL-18 within the first 24 hours (all P<0.05)
Histology: Significantly reduced pancreatic and lung tissue damage on histological scoring
IFNα treatment (4.0×10⁵ U/kg) showed similar benefits, reducing mortality to 33.3% (4/12)
Why it matters
Severe acute pancreatitis kills approximately 20-30% of patients and has no specific pharmacological treatment beyond supportive care. The immune system plays a critical role — early hyperinflammation causes organ damage, while subsequent immunosuppression leads to infection and death. Thymosin alpha-1 addresses both problems: it modulates inflammation while boosting T-cell immunity. As an approved drug in some countries for hepatitis treatment, it could potentially be repurposed for pancreatitis relatively quickly.
How the study worked
One hundred forty-four Sprague-Dawley rats were randomly divided into four groups: control (saline), SAP (5% sodium taurocholate via cholangiopancreatic duct + saline IV), TA1-treated (SAP + 26.7 µg/kg TA1 IV), and IFNα-treated (SAP + 4.0×10⁵ U/kg IFNα IV). Blood was collected at 3, 12, and 24 hours post-surgery for T-cell subset analysis, enzyme markers, cytokines, and procalcitonin. Pancreatic and lung tissues were evaluated by H&E staining with histological scoring. Survival was tracked through the study period.
What this study cannot tell us
This is a rat model of pancreatitis induced by sodium taurocholate, which mimics biliary pancreatitis but may not represent all causes of SAP in humans. The survival data came from subgroups of only 12 rats each, limiting statistical power for mortality comparisons. The 24-hour observation window for biomarkers is very short — longer-term effects are unknown. The mechanism by which TA1 modulates the immune response in pancreatitis is not fully elucidated. Translation to human clinical practice requires clinical trials.
How to read the evidence
This is a well-designed randomized preclinical study with 144 rats across four groups, including appropriate controls. The survival, immunological, biochemical, and histological endpoints provide comprehensive evidence. However, small group sizes for survival analysis and the animal model setting limit the evidence to preclinical level.
When this study was published
Published in 2015, this study contributed to ongoing research into thymosin alpha-1 for critical illness. Interest in TA1 has continued to grow, particularly after studies during the COVID-19 pandemic explored its use in severe respiratory infections.
The bigger picture
Thymosin alpha-1 is a 28-amino-acid peptide naturally produced by the thymus gland that modulates immune function. It is approved in over 30 countries for hepatitis B treatment and has been studied in various critical illness settings including sepsis and severe respiratory infections. This study adds severe pancreatitis to the growing list of conditions where TA1's immune-modulating properties may be beneficial, fitting into a broader trend of exploring immunomodulatory peptides for acute inflammatory diseases.
Questions still open
- Could thymosin alpha-1 be given to critically ill patients with severe acute pancreatitis alongside standard intensive care to improve survival?
- Is thymosin alpha-1's benefit primarily from boosting immune function, reducing inflammation, or both?
- Would earlier administration of TA1 (before full SAP development) provide even greater protection?
Common questions
What is thymosin alpha-1 and how does it boost immunity?
Why is severe acute pancreatitis so dangerous and hard to treat?
Read the original research
Efficacy of thymosin α1 and interferon α for the treatment of severe acute pancreatitis in a rat model.
Molecular medicine reports, 12(5), 6775-81
Citation
Wang, Xiaoqin; Zeng, Xiaoyan; Yang, Bo; Zhao, Shan; Chen, Wei; Guo, Xuan. (2015). Efficacy of thymosin α1 and interferon α for the treatment of severe acute pancreatitis in a rat model.. Molecular medicine reports, 12(5), 6775-81. https://doi.org/10.3892/mmr.2015.4277